GNI Group Ltd.

Equities

2160

JP3386370005

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 10:15:47 2024-05-07 pm EDT			5-day change	1st Jan Change
2,452 ^JPY	+1.57%		+0.78%	-13.39%

Mar. 19	Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy	MT
Feb. 14	GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024	CI

GNI Group Ltd. Appoints of Kazuhiro Kawauchi as Chief Business Development Officer, Effective from January 1, 2023

December 29, 2022 at 02:10 am EST

GNI Group Ltd. announced appointment of Kazuhiro Kawauchi as Chief Business Development Officer, Effective from January 1, 2023. Career summary of Kazuhiro Kawauchi: Kyowa Hakko Kirin Co. Ltd. April 1986 Sapporo Brunch, Pharmaceutical Department (July), April 2017 Deputy Director, Corporate Strategy and Planning Group1, Corporate Strategy.

Latest news about GNI Group Ltd.

Jefferies Adjusts GNI Group’s Price Target to 4,100 Yen From 3,000 Yen, Keeps at Buy	Mar. 19	MT
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending December 2024	Feb. 14	CI
Jefferies Upgrades GNI to Buy From Hold, Adjusts Price Target to 3,000 Yen From 1,500 Yen	Nov. 17	MT
GNI Group Revises Fiscal 2023 Forecast Upwards after Subsidiaries Show Better-than-Expected Sales, Foreign Exchange Rates	Nov. 05	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2023	Nov. 05	CI
GNI Group Ltd. Announces New Management Structure	23-09-28	CI
GNI Group Ltd. Announces New Management Structure	23-09-28	CI
GNI Group Plans to Buy Portion of Elutia's Orthobiologics Business	23-09-20	MT
Wall Street Set to Open Marginally Lower as Fed Kicks Off September Policy Meeting	23-09-19	MT
Equity Futures Trend Higher as Investors Expect No Rate Hike From Fed	23-09-19	MT
North American Morning Briefing : Stock Futures Lack Momentum as Fed Decision Looms	23-09-19	DJ
Elutia Sells Orthobiologics Business Unit For Up to $35 Million	23-09-18	MT
GNI Group issues 1,350 Stock Acquisition Rights	23-09-12	MT
GNI Group to Issue 1,350 Stock Options; Shares Up 3%	23-08-28	MT
GNI Subsidiary Cullgen Closes Series C Funding	23-08-23	MT
GNI Group Ltd. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2023	23-08-03	CI
GNI Group Invests in Shanghai JIUCE Medical Device Technology via Subsidiary	23-08-02	MT
GNI Completes Investment in Shanghai JIUCE for China Expansion	23-08-02	MT
Gni Group Ltd. Announces Notice of Executive Officer Appointment	23-07-03	CI
Jefferies Downgrades GNI Group to Hold From Buy, Adjusts Price Target to 1,500 Yen From 1,300 Yen	23-06-19	MT
Japan Shares Rise as Central Bank Maintains Policy Status Quo; Toyota to Receive 120 Billion Yen of Subsidies	23-06-16	MT
GNI Group Unit, Astellas Pharma Partner to Discover Innovative Protein Degraders	23-06-16	MT
GNI Group Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
GNI Group Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year 2023	23-05-15	CI
Beijing Continent Achieves Mid-Point Subject Enrollment for F351 Phase III Clinical Trial in China	23-05-09	CI

Chart GNI Group Ltd.

Duration

Period

More charts

Company Profile

GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for GNI Group Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,414 JPY

Average target price

4,100 JPY

Spread / Average Target

+69.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GNI GROUP LTD.	-13.39%	791M
MODERNA, INC.	+21.74%	46.81B
IQVIA HOLDINGS INC.	-0.97%	41.37B
LONZA GROUP AG	+47.07%	41.29B
CELLTRION, INC.	-3.52%	28.87B
ICON PUBLIC LIMITED COMPANY	+11.12%	26.06B
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.13B
MEDPACE HOLDINGS, INC.	+31.18%	12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.08B
BIO-TECHNE CORPORATION	+0.39%	11.96B

Other Biotechnology & Medical Research